19 citations
,
June 2010 in “Journal of acupuncture and meridian studies” A plant extract was found to effectively block an enzyme related to male hormone-related diseases.
47 citations
,
January 2003 in “Current opinion in urology” A new drug, dutasteride, is at least as effective as the older drug, finasteride, for treating enlarged prostate and may have additional uses.
5 citations
,
January 2001 in “Advances in protein chemistry” 5α-reductase inhibitors help treat disorders caused by DHT and have potential for future therapies.
13 citations
,
August 2007 in “Bioorganic & medicinal chemistry letters” A new compound effectively inhibits human 5α-reductase 1.
April 2017 in “Actas urológicas españolas” 5-alpha reductase inhibitors increase the risk of sexual dysfunction in patients treating enlarged prostate but not in those treating hair loss.
March 2023 in “Translational Andrology and Urology” 5-alpha reductase inhibitors, like finasteride and dutasteride, are used for prostate issues, hair loss, and excessive hair growth, may help with COVID-19, but can cause sexual and mental health side effects, and their use in preventing prostate cancer needs more examination.
January 2025 in “Journal of Crohn s and Colitis” Tofacitinib is effective and safe for elderly patients with ulcerative colitis.
66 citations
,
April 2017 in “International Journal of Andrology” Men taking 5α-reductase inhibitors for enlarged prostate have a higher chance of experiencing reduced sexual desire and erectile dysfunction.
10 citations
,
March 2023 in “Journal of Chemistry” New compounds show promise for treating benign prostate hyperplasia with fewer side effects.
May 2023 in “Acta Oncologica” 5α-reductase inhibitors do not improve survival in oesophageal and gastric cancer patients.
November 2025 in “Drug Testing and Analysis” Epristeride's metabolism involves key metabolites and proteins, affecting its use in doping tests.
5 citations
,
January 2014 in “Molecular Simulation” A new compound may treat benign prostatic hyperplasia better than finasteride.
6 citations
,
September 2024 in “Journal of the American Academy of Dermatology” Oral 5-alpha reductase inhibitors do not increase breast cancer or benign breast disorder risk in women.
7 citations
,
August 2006 in “Maturitas” Cimicifuga racemosa extract may help prevent and treat prostate issues by inhibiting 5α-reductase.
July 2023 in “Dermatology and Therapy” 5-Alpha Reductase Inhibitors are effective for male hair loss and some skin conditions, but their effectiveness in women and safety concerns require careful use.
January 2016 in “Archivio italiano di urologia, andrologia” The document concludes that the risk of sexual side effects from 5-alpha-reductase inhibitors is low and often temporary, but more research is needed on potential permanent effects.
2 citations
,
October 2021 in “Asian Journal of Andrology” Medications for hair loss and prostate issues can significantly increase the risk of sexual side effects and other negative symptoms.
May 2018 in “Más dermatología” The higher dose supplement was more effective in treating female hair loss.
6 citations
,
August 2013 in “한국응용생명화학회지” Certain natural compounds can block an enzyme linked to prostate enlargement and hair loss, showing potential for new treatments.
2 citations
,
April 2021 in “Canadian Journal of Urology” Five-alpha reductase inhibitors, like finasteride and dutasteride, can treat enlarged prostates, improve urination, reduce need for prostate surgery, and lower the risk of prostate cancer, but may increase the risk of higher grade prostate cancer. They can also treat male pattern baldness.
90 citations
,
March 2017 in “JAMA Internal Medicine” Men over 66 taking medication for prostate enlargement have a higher risk of depression and self-harm, especially in the first 18 months of treatment.
2 citations
,
December 2021 in “International Journal of Andrology” Most legal cases about 5α-reductase inhibitors, drugs for hair loss and prostate issues, complain about side effects and delayed cancer diagnosis, with most lawsuits settled out of court.
21 citations
,
March 2018 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” 5-alpha-reductase inhibitors may help stabilize or slow down hair loss in some frontal fibrosing alopecia patients, but more research is needed to confirm their effectiveness and safety.
4 citations
,
October 2018 in “International Braz J Urol” Taking 5-alpha reductase inhibitors does not increase the risk of breast cancer in men.
33 citations
,
January 2016 in “Skin appendage disorders” The document concludes that sexual and psychiatric side effects from 5-alpha-reductase inhibitors are reported, but more high-quality research is needed to understand how often they occur.
March 2020 in “Section 5: Patient safety and quality assurance” Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.
218 citations
,
December 2011 in “Advances in Urology” The document concludes that the 5 alpha-reductase enzymes are important in steroid metabolism and related to various human diseases, with inhibitors used to treat conditions like male pattern baldness and prostate issues.
July 2024 in “Journal of Investigative Dermatology” 5-alpha reductase inhibitors don't increase breast cancer or benign breast disorder risk in women.
31 citations
,
January 2017 in “Advances in Experimental Medicine and Biology” Low testosterone and 5α-reductase inhibitors can harm men's metabolic and sexual health; testosterone therapy may help, but discussing 5α-RIs' side effects is important.
237 citations
,
December 2001 in “Urology” Blocking the enzyme 5α-reductase can shrink the prostate and help treat enlarged prostate issues.